scholarly journals Immune Responses to Varicella Zoster Virus and Effective Vaccines

2021 ◽  
Vol 51 (3) ◽  
pp. 103-111
Author(s):  
Su Jeen Lee ◽  
Hun Kim ◽  
Kee-Jong Hong ◽  
Jae-Hwan Nam
Keyword(s):  
Immune Responses ◽  
Varicella Zoster Virus ◽  
Varicella Zoster

scholarly journals Varicella‐Zoster Virus–Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine

2009 ◽  
Vol 200 (7) ◽  
pp. 1068-1077 ◽  
Author(s):  
Adriana Weinberg ◽  
Jane H. Zhang ◽  
Michael N. Oxman ◽  
Gary R. Johnson ◽  
Anthony R. Hayward ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
Immune Responses ◽  
Varicella Zoster Virus ◽  
Zoster Vaccine ◽  
Varicella Zoster

scholarly journals Herpes zoster after lung transplantation boosts varicella zoster virus–specific adaptive immune responses

2016 ◽  
Vol 35 (12) ◽  
pp. 1435-1442 ◽  
Author(s):  
Nicole M. van Besouw ◽  
Peter Th.W. van Hal ◽  
Joke M. Zuijderwijk ◽  
Ronella de Kuiper ◽  
Rogier A.S. Hoek ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
Immune Responses ◽  
Lung Transplantation ◽  
Varicella Zoster Virus ◽  
Adaptive Immune Responses ◽  
Varicella Zoster ◽  
Adaptive Immune

scholarly journals Persistence of Immune Response to an Adjuvanted Varicella-Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S415-S415 ◽  
Author(s):  
Karlis Pauksens ◽  
Stephanie Volpe ◽  
Tino F Schwarz ◽  
Jan Smetana ◽  
Nicole Toursarkissian ◽  
...  
Keyword(s):  
Immune Responses ◽  
Varicella Zoster Virus ◽  
Geometric Mean ◽  
Intracellular Cytokine Staining ◽  
Post Dose ◽  
Serious Adverse Events ◽  
Activation Markers ◽  
Varicella Zoster ◽  
Age Cohorts ◽  
Humoral Immune

Abstract Background In the ZOE-50 and ZOE-70 clinical trials, the candidate herpes-zoster subunit vaccine (HZ/su; 50µg varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) demonstrated high efficacy against HZ, with limited waning over 4 years and consistent efficacy across age cohorts. In adults ≥60 years of age, the immune responses elicited by 2 HZ/su doses administered 2 months apart persisted for at least 6 years.1 Here we report immunogenicity and safety 9 years post-initial vaccination. Methods This Phase IIIB, open, long-term extension study (NCT02735915) followed 70 participants who received 2 HZ/su doses in the initial trial (NCT00434577). Blood samples to evaluate the persistence of cellular (intracellular cytokine staining) and humoral (ELISA) immune responses were taken at 9 years post-initial vaccination. Limited safety follow-up was performed (1 visit). Results All 70 participants (mean age at dose 1: 72.3 years; 61.4% female) were included in the according-to-protocol analysis. The fold increases over pre-vaccination in the frequency of gE-specific CD4+ T-cells expressing ≥2 activation markers plateaued after 4 years post-dose 1 (year 4: 3.4, year 5: 3.0, year 6: 3.4, year 9: 3.4). Anti-gE antibody geometric mean concentrations were also stable from year 4 onwards (Table 1) and remained above the pre-vaccination value of 1213.1mIU/mL. Cellular and humoral responses at year 9 were similar across age strata (60–69, ≥70 years). No vaccine-related serious adverse events nor suspected HZ episodes were reported. Conclusion In adults ≥60 years of age, HZ/su-induced cellular and humoral immune responses remained above pre-vaccination levels for at least 9 years post-initial vaccination, confirming immune persistence predictions2 based on 6-year data. Disclosures S. Volpe, GSK: Employee, Salary; T. F. Schwarz, GSK: Investigator and Scientific Advisor, Consulting fee; J. Smetana, GSK: Investigator, personal fees; 
S. Ravault, GSK: Employee, GSK shares and Salary; M. P. David, GSK: Employee, Salary and stock; A. Bastidas, GSK: Employee, Salary; L. Oostvogels, GSK: Employee and Shareholder, Salary and shares

scholarly journals Viral Load, Clinical Disease Severity and Cellular Immune Responses in Primary Varicella Zoster Virus Infection in Sri Lanka

PLoS ONE ◽  
2008 ◽  
Vol 3 (11) ◽  
pp. e3789 ◽  
Author(s):  
Gathsaurie Neelika Malavige ◽  
Louise Jones ◽  
S. D. Kamaladasa ◽  
A. Wijewickrama ◽  
S. L. Seneviratne ◽  
...  
Keyword(s):  
Viral Load ◽  
Sri Lanka ◽  
Virus Infection ◽  
Immune Responses ◽  
Varicella Zoster Virus ◽  
Disease Severity ◽  
Varicella Zoster Virus Infection ◽  
Varicella Zoster ◽  
Cellular Immune Responses ◽  
Cellular Immune

scholarly journals Influence of Age and Nature of Primary Infection on Varicella‐Zoster Virus–Specific Cell‐Mediated Immune Responses

2010 ◽  
Vol 201 (7) ◽  
pp. 1024-1030 ◽  
Author(s):  
Adriana Weinberg ◽  
Ann A. Lazar ◽  
Gary O. Zerbe ◽  
Anthony R. Hayward ◽  
Ivan S. F. Chan ◽  
...  
Keyword(s):  
Immune Responses ◽  
Varicella Zoster Virus ◽  
Primary Infection ◽  
Specific Cell ◽  
Varicella Zoster

scholarly journals Varicella-Zoster Virus–Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults

2017 ◽  
Vol 199 (2) ◽  
pp. 604-612 ◽  
Author(s):  
Adriana Weinberg ◽  
Jennifer Canniff ◽  
Nadine Rouphael ◽  
Aneesh Mehta ◽  
Mark Mulligan ◽  
...  
Keyword(s):  
Older Adults ◽  
Immune Responses ◽  
Varicella Zoster Virus ◽  
Zoster Vaccine ◽  
Varicella Zoster ◽  
Cellular Immune Responses ◽  
Cellular Immune
Sign in / Sign up

Export Citation Format

Share Document